CSI Market
Sign In | Register

Nektar Therapeutics (NKTR) Annual Cash Flow Statement

Annual · GAAP · USD millions
Access NKTR quarterly Cash Flow →
Observing cash flow movements over recent quarters helps explain how Nektar Therapeutics adapts cash usage as operating conditions change.
View historic periods: Download as CSV:
Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.
Annual Report, GAAP in USD millions
ITEM 		(Dec 31 2025)
12 Months 		(Dec 31 2024) (Dec 31 2023) (Dec 31 2022) (Dec 31 2021)
Operating Activities
Income-164.08
Depreciation & amortization1.03
Amortization of Other Assets-5.51
Increase (Decrease) in Deferred Revenue0.00
Impairment of Long-Lived Assets Held-for-use4.44
Provision For Loan Losses Expensed0.00
Increase (Decrease) in Inventories0.00
Research and Development in Process0.00
Gain (Loss) on Disposition of Property Plant Equipment0.00
Share-based Compensation12.65
Income (Loss) from Equity Method Investments8.73
Foreign Currency Transaction Gain (Loss), before Tax, Total0.00
Non Cash Royalty Revenue Related To Sale Of Future Royalties-54.93
Noncash Interest Expense-
Loss From Redemption Premium And Incremental Interest On Secured Debt-
Write Off Of Deferred Debt Issuance Cost-
Increase Decrease In Accrued Clinical Trial Expenses-
Impairment Of Equipment From Terminated Program-
Accretion Of Discount Net And Other Non Cash Transactions-
Provision For Inventory Obsolescence-
Increase Decrease In Operating Lease Right Of Use Assets Net Of Operating Lease Liabilities-15.16
Income taxes0.00
Losses/ -gains on Investments net0.00
Increase (Decrease) in Accounts Receivable0.00
Increase (Decrease) in Accounts Payable-0.63
Increase (Decrease) in Other Accrued Liabilities-5.79
Deferred Revenue and Customer Advances and Deposits0.00
Prepaid Expense and Other Assets0.00
Other Working Capital-15.45
Other Noncash Income (Expense)0.00
Other net0.00
Payments for (Proceeds from) Other Operating Activities26.18
Discontinued operations0.00
Net Cash flow from Operating Activities-208.51
Investing Activities
Capital Expenditures-0.17
Sale of Capital Items0.00
Proceeds from Maturities, Prepayments and Calls of Available-for-sale Securities284.68
Payments to Acquire Available-for-sale Securities, Debt-285.01
Real Estate Investments0.00
Advance Payments For Property And Equipment-
Payment For Transaction Costs For Sale Of Pulmonary Assets-
Proceeds From Sale Of The Huntsville Manufacturing Facility Net-
Payment Of Transaction Costs And Working Capital Adjustment From The Sale Of Manufacturing Facility-
Proceeds From Payments For Sale Of Huntsville Manufacturing Facility Net-0.70
Increase (Decrease) in Restricted Cash0.00
Payments for (Proceeds from) Loans0.00
Payments for (Proceeds from) Deposits0.00
Payments for (Proceeds from) Other Investments0.00
Payments for (Proceeds from) Federal Reserve and FHLB0.00
Acquisition Net of Cash Acquired0.00
Interest in Subsidiaries and Affiliates0.00
Sale of businesses0.00
Accounts payable0.00
Receivables0.00
Payments for (Proceeds from) Other Investing Activities0.00
Other Net0.00
Discontinued operations0.00
Net Cash Flow from Investing Activities-1.20
Financing Activities
Short-term debt Net0.00
Other borrowing transactions0.00
Long-term debt - borrowings0.00
Long-term debt - repayments0.00
Federal Home Loan Bank and Federal Funds0.00
Issuances / -repurchases of Comm. Stock107.82
Partnership and Parent Transactions0.00
Issuances / -repurchases of Pref. Stock0.00
Deposits, Annuities, Contract Holders Funds0.00
Other financing activities net0.00
Other net28.50
Repayment Of And Proceeds From Sale Of Future Royalties Net Of Transaction Costs-
Proceeds From Issuance Of Common Stock Net Of Issuance Costs-
Proceeds From Sale Of Potential Future Royalties Net Of Transaction Costs-
Repayment Of Proceeds From Sale Of Future Royalties Net Of Transaction Costs-
Proceeds From Sale Of Future Royalties Net-
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents44.25
Proceeds From Sale Of Future Royalties-
Payments of Dividends, Preferred Stock and Preference Stock0.00
Dividends paid0.00
Net Cash Flow from Financing Activities180.57
Effect of exchange rate on cash flow0.01
Discontinued operations0.00
Free Cash Flow-208.68
Total Cash Flow-29.14
4 historic quarters locked

Sign in to unlock the full Nektar Therapeutics cash flow history.

Sign In Create Free Account

About Nektar Therapeutics Annual Cash Flow Statement

What this statement shows

This page presents issuer-reported cash flow data, including operating, investing, financing, net, and free cash flow, as disclosed in SEC 10-K filings and normalized by CSIMarket.

Source & verification

Last updated

  • Page updated:
  • Data lineage: SEC filings - XBRL extraction - normalization in the CSIMarket.com database.
  • Accession: 0001193125-26-104547

Figures are derived from filed reports and may be restated. Historical data is subject to revision.

Untitled Document 





                    


    



  Get the full CSIMarket dataset:
  Subscribe
  API
  License